PALO ALTO, Calif. — BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today shared positive results from the Japan Phase III trial of acoramidis in adults with transthyretin-mediated amyloid with cardiomyopathy (ATTR-CM), conducted by Alexion, AstraZeneca Rare Disease. Results showed consistency to those...
treatment News
PALO ALTO, Calif. — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced that updated data from CANaspire, its Phase 1/2 clinical trial of BBP-812, an investigational intravenous (IV) adeno-associated virus serotype 9 (AAV9) gene therapy for the treatment...
PALO ALTO, Calif. & LUGANO, Switzerland – BridgeBio Pharma, Inc. (Nasdaq: BBIO), through its affiliate QED Therapeutics, Inc., and Helsinn Group today announced that the US Food and Drug Administration (FDA) has approved TRUSELTIQ™ (infigratinib) under the accelerated approval program for the treatment of patients with previously-treated locally advanced or...
New York, NY – Bristol Myers Squibb (NYSE: BMY) today announced that the pivotal Phase 3 KRYSTAL-12 study, evaluating KRAZATI® (adagrasib) as a monotherapy in patients with pretreated locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation, met the primary endpoint of progression-free survival (PFS) and...
New York, NY – It isn’t often that a single company has an advisory committee meeting for one product and an FDA decision for another in the same week. Even more unusual is when the two drugs are of the same therapeutic class. That’s what’s happening this week for Bristol...
PRINCETON, N.J. – Bristol Myers Squibb (NYSE: BMY) announced positive topline results from the Phase 3 CheckMate -648 trial evaluating treatment with Opdivo (nivolumab) plus chemotherapy or Opdivo plus Yervoy (ipilimumab) in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC). In the study, Opdivo plus chemotherapy demonstrated a statistically...
PRINCETON, N.J. – Bristol Myers Squibb on Saturday released results from the Phase III CheckMate -8HW study showing that the combination of its PD-1 inhibitor Opdivo (nivolumab) and its CTLA-4 blocker Yervoy (ipilimumab) improved progression-free survival in certain metastatic colorectal cancer patients when used in the first-line setting. Patients treated...
PRINCETON, N.J. – Bristol Myers Squibb is pulling the plug on a trial investigating what it calls the Opdulag combination, a pairing of Opdivo (nivolumab) and relatlimab, in patients with microsatellite stable metastatic colorectal cancer. In an announcement on Friday, BMS said that data from the Phase III trial of...
PRINCETON, N.J. – Bristol Myers Squibb (NYSE: BMY) today announced results from the Phase 3 CheckMate -648 trial, in which two Opdivo-based treatment combinations — Opdivo (nivolumab) plus chemotherapy and Opdivo plus Yervoy (ipilimumab) — demonstrated a statistically significant and clinically meaningful overall survival (OS) benefit compared to chemotherapy at...
PRINCETON, N.J. – Bristol Myers Squibb (NYSE:BMY) today announced that additional data from multiple studies evaluating Zeposia (ozanimod) in ulcerative colitis (UC) were presented at Digestive Disease Week® (DDW), taking place virtually May 21-23, 2021. These data deepen the understanding of Zeposia and reinforce Bristol Myers Squibb’s commitment to understanding...